214 related articles for article (PubMed ID: 36059442)
1. A Novel hepatocellular carcinoma specific hypoxic related signature for predicting prognosis and therapeutic responses.
Cai G; Zhu J; Ning D; Li G; Zhang Y; Xiong Y; Liang J; Yu C; Chen X; Liang H; Ding Z
Front Immunol; 2022; 13():997316. PubMed ID: 36059442
[TBL] [Abstract][Full Text] [Related]
2. A cellular senescence-related classifier based on a tumorigenesis- and immune infiltration-guided strategy can predict prognosis, immunotherapy response, and candidate drugs in hepatocellular carcinoma.
Luo Y; Liu H; Fu H; Ding GS; Teng F
Front Immunol; 2022; 13():974377. PubMed ID: 36458010
[TBL] [Abstract][Full Text] [Related]
3. Hypoxic Characteristic in the Immunosuppressive Microenvironment of Hepatocellular Carcinoma.
Mo Z; Liu D; Rong D; Zhang S
Front Immunol; 2021; 12():611058. PubMed ID: 33679749
[No Abstract] [Full Text] [Related]
4. Construction of a Combined Hypoxia-related Genes Model for Hepatocellular Carcinoma Prognosis.
Ren L; Pan X; Ning L; Gong D; Huang J; Deng K; Xie L; Zhang Y
Curr Comput Aided Drug Des; 2023; 19(2):150-161. PubMed ID: 36567292
[TBL] [Abstract][Full Text] [Related]
5. Identification of Hypoxia-Related Subtypes, Establishment of Prognostic Models, and Characteristics of Tumor Microenvironment Infiltration in Colon Cancer.
Wang C; Tang Y; Ma H; Wei S; Hu X; Zhao L; Wang G
Front Genet; 2022; 13():919389. PubMed ID: 35783281
[No Abstract] [Full Text] [Related]
6. Construction of a risk score prognosis model based on hepatocellular carcinoma microenvironment.
Zhang FP; Huang YP; Luo WX; Deng WY; Liu CQ; Xu LB; Liu C
World J Gastroenterol; 2020 Jan; 26(2):134-153. PubMed ID: 31969776
[TBL] [Abstract][Full Text] [Related]
7. The combined signatures of hypoxia and cellular landscape provides a prognostic and therapeutic biomarker in hepatitis B virus-related hepatocellular carcinoma.
Chen S; Gao Y; Wang Y; Daemen T
Int J Cancer; 2022 Sep; 151(5):809-824. PubMed ID: 35467769
[TBL] [Abstract][Full Text] [Related]
8. Hypoxia Enhances Tumor-Stroma Crosstalk that Drives the Progression of Hepatocellular Carcinoma.
Cho Y; Cho EJ; Lee JH; Yu SJ; Kim YJ; Kim CY; Yoon JH
Dig Dis Sci; 2016 Sep; 61(9):2568-77. PubMed ID: 27074919
[TBL] [Abstract][Full Text] [Related]
9. Integrated investigation of the clinical implications and targeted landscape for RNA methylation modifications in hepatocellular carcinoma.
Zhang J; Gao J; Hu M; Xu S; Cheng C; Zheng W; Zhang J
Eur J Med Res; 2023 Jan; 28(1):46. PubMed ID: 36707911
[TBL] [Abstract][Full Text] [Related]
10. Analysis of angiogenesis-related subtypes of hepatocellular carcinoma and tumor microenvironment infiltration feature in hepatocellular carcinoma.
Li W; Wu R; Zhang S; Zhao Y; Li L; Hu Z; Su Q; Mang Y; Zhang X; Dong Y; Zheng K; Ran J; Li L
Clin Transl Oncol; 2023 Jul; 25(7):2099-2115. PubMed ID: 36708372
[TBL] [Abstract][Full Text] [Related]
11. 8DEstablishment and validation of a hypoxia-related signature predicting prognosis in hepatocellular carcinoma.
Cai C; Yang L; Zhou K
BMC Gastroenterol; 2021 Dec; 21(1):463. PubMed ID: 34895169
[TBL] [Abstract][Full Text] [Related]
12. Histone Acetylation Regulator-Mediated Acetylation Patterns Define Tumor Malignant Pathways and Tumor Microenvironment in Hepatocellular Carcinoma.
Xu Y; Liao W; Luo Q; Yang D; Pan M
Front Immunol; 2022; 13():761046. PubMed ID: 35145517
[TBL] [Abstract][Full Text] [Related]
13. HIF-1α promoted vasculogenic mimicry formation in hepatocellular carcinoma through LOXL2 up-regulation in hypoxic tumor microenvironment.
Wang M; Zhao X; Zhu D; Liu T; Liang X; Liu F; Zhang Y; Dong X; Sun B
J Exp Clin Cancer Res; 2017 Apr; 36(1):60. PubMed ID: 28449718
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive analysis of tumour mutation burden and the immune microenvironment in hepatocellular carcinoma.
Xie F; Bai Y; Yang X; Long J; Mao J; Lin J; Wang D; Song Y; Xun Z; Huang H; Yang X; Zhang L; Mao Y; Sang X; Zhao H
Int Immunopharmacol; 2020 Dec; 89(Pt A):107135. PubMed ID: 33189609
[TBL] [Abstract][Full Text] [Related]
15. Identification of a prognostic and therapeutic immune signature associated with hepatocellular carcinoma.
Peng Y; Liu C; Li M; Li W; Zhang M; Jiang X; Chang Y; Liu L; Wang F; Zhao Q
Cancer Cell Int; 2021 Feb; 21(1):98. PubMed ID: 33568167
[TBL] [Abstract][Full Text] [Related]
16. A Novel Hypoxic-Angiogenesis-Immune-Related Gene Model for Prognostic and Therapeutic Effect Prediction in Hepatocellular Carcinoma Patients.
Lv W; Yao Q
Dis Markers; 2022; 2022():9428660. PubMed ID: 35069936
[TBL] [Abstract][Full Text] [Related]
17. Identification and Validation of a Novel Tumor Microenvironment-Related Prognostic Signature of Patients With Hepatocellular Carcinoma.
Li R; Zhao W; Liang R; Jin C; Xiong H
Front Mol Biosci; 2022; 9():917839. PubMed ID: 35847972
[No Abstract] [Full Text] [Related]
18. Hypoxia signaling in hepatocellular carcinoma: Challenges and therapeutic opportunities.
Sin SQ; Mohan CD; Goh RMW; You M; Nayak SC; Chen L; Sethi G; Rangappa KS; Wang L
Cancer Metastasis Rev; 2023 Sep; 42(3):741-764. PubMed ID: 36547748
[TBL] [Abstract][Full Text] [Related]
19. Hypoxia-based classification and prognostic signature for clinical management of hepatocellular carcinoma.
Li K; Yang Y; Ma M; Lu S; Li J
World J Surg Oncol; 2023 Jul; 21(1):216. PubMed ID: 37481543
[TBL] [Abstract][Full Text] [Related]
20. Identification of a Tumor Immunological Phenotype-Related Gene Signature for Predicting Prognosis, Immunotherapy Efficacy, and Drug Candidates in Hepatocellular Carcinoma.
Tang Y; Guo C; Yang Z; Wang Y; Zhang Y; Wang D
Front Immunol; 2022; 13():862527. PubMed ID: 35493471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
